Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interferenc...

Full description

Bibliographic Details
Main Authors: Sockolosky, Jonathan T., Ho, Chia Chi M., Almo, Steven C., Garcia, K. Christopher, Dougan, Michael, Kauke, Monique Jacqueline, Ploegh, Hidde, Ingram, Jessica R.
Other Authors: Massachusetts Institute of Technology. Department of Biology
Format: Article
Language:en_US
Published: National Academy of Sciences (U.S.) 2016
Online Access:http://hdl.handle.net/1721.1/105539
https://orcid.org/0000-0002-0013-3941
https://orcid.org/0000-0002-1090-6071

Internet

http://hdl.handle.net/1721.1/105539
https://orcid.org/0000-0002-0013-3941
https://orcid.org/0000-0002-1090-6071

Similar Items